EUCTR2005-005255-18-GB进行中（未招募）1 期
A single arm phase II study to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536, administered once every 3 weeks in patients with advanced metastatic hormone-refractory prostate cancer - BI 2536 in advanced metastatic hormone-refractory prostate cancer
Boehringer Ingelheim UK Ltd0 个研究点目标入组 50 人开始时间: 2006年3月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Male patient age >18 years.
- •Signed informed consent.
- •Able to comply with protocol requirements.
- •Patients with histologically, cytologically or biochemically documented metastatic adenocarcinoma of the prostate, clinically refractory or resistant to hormone therapy, as documented by progression following at least one hormonal therapy, which must include orchidectomy or gonadotropin releasing hormone agonist (GnRHa).
- •Patients with Progressive Disease (PD). PD is defined as a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which document progressively increasing PSA values. Patients with progression of measurable disease (RECIST) or progression of bone disease must also fit the criterion for PSA progression.
- •Patients must have documented progression (as defined above) following anti-androgen withdrawal of 4 weeks duration for flutamide and 6 weeks for bicalutamide or nilutamide. For a patient who has withdrawn from anti-androgen therapy less than 6 months prior to inclusion in the trial, one of the following criteria is also required:
- •Following completion of the anti-androgen withdrawal period one PSA measurement should be higher than the last pre-withdrawal PSA.
- •Following the completion of the anti-androgen withdrawal period if the PSA value has decreased, a patient can still qualify if 2 increases in PSA are documented after the post- withdrawal nadir.
- •PSA = 10 ng/ml.
- •A predicted life expectancy of at least 12 weeks.
- •A maximum of one prior treatment with either chemotherapy or other non-hormonal treatment modality.
- •ECOG performance status 0-1.
- •Stable analgesia requirements.
- •INR Prothrombin time (PT) and partial thromboplastin time (PTT) <1.5 upper limit of normal.
- •Adequate bone marrow function defined as absolute neutrophil count (ANC) = 1.5 x 109l, Platelet count = 100 x 109/l.
- •Haemoglobin = 9.0 mg/dl.
- •Serum Albumin = 2.0 g/l.
- •Castrate testosterone level [< 20 ng/dl or <0.69nM (nM/L x 28.8 = ng/dl)] must be maintained during the duration of the trial by orchidectomy or medical castration.
- •Patients on oral or intravenous bisphosphonates are allowed to enter the trial as long as they have been on bisphosphonates for a minimum of 3 months.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior treatment with more than one cytotoxic chemotherapy regimen.
- •Known or suspected hypersensitivity to the trial drug or their excipients.
- •Persistence of toxicities of prior anti-cancer therapies which are deemed to be clinically relevant.
- •Aspartate amino transferase (ast) or alanine amino transferase (alt) greater than 2.5 times the upper limit of normal, or aspartate amino transferase (ast) or alanine amino transferase (alt) greater than 5 times the upper limit of normal in case of known liver metastases.
- •Bilirubin greater than 1.5 mg/dl (> 26 ?mol/l, Si unit equivalent).
- •Serum creatinine greater than 2.0 g/l.
- •Concomitant intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situation that would limit compliance with trial requirement or which are considered relevant for the evaluation of the efficacy or safety of the trial drug.
- •Systemic corticosteroids taken within the past 28 days before screening (inhaled corticosteroids prescribed for bronchospasm are allowed). Patients on long-term stable-dose steroids for concurrent illness are not excluded.
- •Treatment with any investigational drug within 28 days of trial onset.
- •History of other malignancies which could affect compliance with the protocol or interpretation of results within 5-years. Patients with adequately treated basal or squamous cell skin cancer are generally eligible.
- •Patient with history or clinical evidence of CNS disease or brain metastases.
- •Patients with symptoms of impending or established spinal cord compression.
- •Radiotherapy within the past four weeks prior to treatment with the trial drug.
- •Prior radioisotope therapy (except radium-223 which is permissible).
- •Immunotherapy within the past four weeks prior to treatment with the trial drug.
- •Patients unable to comply with the protocol.
- •Active alcohol or drug abuse.
- •Patients who do not use adequate contraception.
研究者
相似试验
招募中
2 期
on-randomized clinical trial to assess the effect of a medication against cytomegalovirus in patients who are not infected originally cytomegalovirus but who have received renal transplantation from donors that are infected by cytomegalovirus.CMV seronegative patients that have received kidney allografts from CMV seropositive donorsV01-Y98RBR-8gcx9mTheraclone Sciences, Inc
招募中
2 期
A clinical trial to evaluate the effect of low-dose atovaquone on the prevention of pneumocystis pneumonia in patients with rheumatic diseasesRheumatic DiseasesJPRN-jRCTs031210557Furuta Syunsuke50
已完成
2 期
Revlimid® Early Stage Poor prognosis Chronic lymphocytic leukaemia (CLL) TrialCancerISRCTN84606869Christie NHS Foundation Trust (UK)40
进行中（未招募）
1 期
A single arm phase II study to investigate the use of Lenalidomide in the treatment of patients with early stage CLL associated with poor prognostic factors. - RESPeCT: Revlimid Early Stage Poor prognosis CLL Trialntreated early stage Chronic Lymphocytic Leukaemia (CLL) (Binet stage A) with poor prognostic factors.MedDRA version: 9.1 Level: LLT Classification code 10008958 Term: Chronic lymphocytic leukaemiaEUCTR2009-011078-14-GBThe Christie NHS Foundation Trust40
进行中（未招募）
1 期
A phase II study of linperlisib (YY-20394) in patients with relapsed or refractory peripheral T/NK cell or Cutaneous T Cell lymphomaCTIS2022-501431-16-00Shanghai Yingli Pharmaceutical Co. Ltd.107